FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378611462> ?p ?o ?g. }

• W4378611462 endingPage "A268" @default.
• W4378611462 startingPage "A268" @default.
• W4378611462 abstract "Abstract Introduction Lower-sodium oxybate (LXB; Xywav®), which contains the same active moiety as higher-sodium oxybate (SXB; Xyrem®) but with 92% less sodium, is approved by the US Food and Drug Administration (FDA) for treating cataplexy or excessive daytime sleepiness in patients ≥7 years of age with narcolepsy. LXB is recognized as clinically superior to SXB in narcolepsy by the US FDA due to lower chronic sodium exposure; however, real-world data describing patient preferences and satisfaction are lacking. Methods Transition Experience of persons with Narcolepsy taking Oxybate in the Real-world (TENOR; NCT04803786) was a patient-centric, prospective, observational, noninterventional, virtual-format study of US adults with narcolepsy (type 1 or 2) transitioning from SXB to LXB within the previous/upcoming 7 days. Longitudinal data collected during transition and for 21 weeks thereafter included responses to the Ease of Switching Medications Scale (EOSMS), Forced Preference Questionnaire (FPQ), and Treatment Satisfaction Questionnaire for Medication-version II (TSQM-vII). Results The mean (standard deviation [SD]) age of the 85 participants (narcolepsy type 1, n=45; narcolepsy type 2, n=40) was 40.3 (13.0) years; most were female (73%) and White (87%). Mean (SD) time on current SXB regimen was 57.8 (52.1) months. Nearly all participants took SXB (82/85, 96%) twice nightly prior to transition and LXB (82/84, 98%) twice nightly after transition. Most participants (61/73, 84%) reported that switching from SXB to LXB was “extremely easy, not difficult at all” or “easy” on the EOSMS, and most (59/73, 81%) preferred LXB to SXB on the FPQ. Among participants who preferred LXB, lower sodium content (56/59, 95%) and fewer cardiovascular issues (27/59, 46%) were cited as the most common reasons. There were minimal mean (SD) changes in TSQM-vII scores for global satisfaction (1.1 [18.6]), satisfaction with effectiveness (1.0 [16.8]), side effects (4.1 [23.7]), or convenience (−3.9 [15.2]) after transitioning from SXB to LXB. Conclusion Overall, most participants indicated that switching from SXB to LXB was “easy” or “extremely easy.” Most participants preferred LXB to SXB, primarily because of its lower sodium content. Satisfaction with oxybate treatment was maintained following transition to LXB. Support (if any) Jazz Pharmaceuticals" @default.
• W4378611462 created "2023-05-29" @default.
• W4378611462 creator A5003533420 @default.
• W4378611462 creator A5018754100 @default.
• W4378611462 creator A5019335363 @default.
• W4378611462 creator A5021371072 @default.
• W4378611462 creator A5056007981 @default.
• W4378611462 creator A5073097180 @default.
• W4378611462 creator A5078786005 @default.
• W4378611462 date "2023-05-01" @default.
• W4378611462 modified "2023-10-01" @default.
• W4378611462 title "0611 Treatment Satisfaction and Preferences in People With Narcolepsy Transitioning From Sodium Oxybate to Lower-Sodium Oxybate" @default.
• W4378611462 doi "https://doi.org/10.1093/sleep/zsad077.0611" @default.
• W4378611462 hasPublicationYear "2023" @default.
• W4378611462 type Work @default.
• W4378611462 citedByCount "0" @default.
• W4378611462 crossrefType "journal-article" @default.
• W4378611462 hasAuthorship W4378611462A5003533420 @default.
• W4378611462 hasAuthorship W4378611462A5018754100 @default.
• W4378611462 hasAuthorship W4378611462A5019335363 @default.
• W4378611462 hasAuthorship W4378611462A5021371072 @default.
• W4378611462 hasAuthorship W4378611462A5056007981 @default.
• W4378611462 hasAuthorship W4378611462A5073097180 @default.
• W4378611462 hasAuthorship W4378611462A5078786005 @default.
• W4378611462 hasBestOaLocation W43786114621 @default.
• W4378611462 hasConcept C118552586 @default.
• W4378611462 hasConcept C141071460 @default.
• W4378611462 hasConcept C15744967 @default.
• W4378611462 hasConcept C187212893 @default.
• W4378611462 hasConcept C2775944032 @default.
• W4378611462 hasConcept C2779494582 @default.
• W4378611462 hasConcept C2780163352 @default.
• W4378611462 hasConcept C2780714222 @default.
• W4378611462 hasConcept C71924100 @default.
• W4378611462 hasConceptScore W4378611462C118552586 @default.
• W4378611462 hasConceptScore W4378611462C141071460 @default.
• W4378611462 hasConceptScore W4378611462C15744967 @default.
• W4378611462 hasConceptScore W4378611462C187212893 @default.
• W4378611462 hasConceptScore W4378611462C2775944032 @default.
• W4378611462 hasConceptScore W4378611462C2779494582 @default.
• W4378611462 hasConceptScore W4378611462C2780163352 @default.
• W4378611462 hasConceptScore W4378611462C2780714222 @default.
• W4378611462 hasConceptScore W4378611462C71924100 @default.
• W4378611462 hasIssue "Supplement_1" @default.
• W4378611462 hasLocation W43786114621 @default.
• W4378611462 hasOpenAccess W4378611462 @default.
• W4378611462 hasPrimaryLocation W43786114621 @default.
• W4378611462 hasRelatedWork W2063296436 @default.
• W4378611462 hasRelatedWork W2076728019 @default.
• W4378611462 hasRelatedWork W2084797556 @default.
• W4378611462 hasRelatedWork W2094458128 @default.
• W4378611462 hasRelatedWork W2187198902 @default.
• W4378611462 hasRelatedWork W2348861508 @default.
• W4378611462 hasRelatedWork W2409294555 @default.
• W4378611462 hasRelatedWork W2922719566 @default.
• W4378611462 hasRelatedWork W2980463228 @default.
• W4378611462 hasRelatedWork W3175558241 @default.
• W4378611462 hasVolume "46" @default.
• W4378611462 isParatext "false" @default.
• W4378611462 isRetracted "false" @default.
• W4378611462 workType "article" @default.